Condition Deep-Dives 11 min read·Updated 22 July 2026 Clinician-reviewed

Immunotactoid Glomerulopathy

A UK Consultant Nephrologist on immunotactoid glomerulopathy — a rare but haematology-defining cause of nephrotic-range proteinuria with characteristic hollow microtubular deposits on EM.

  • Clinically Reviewed
  • NHS & NICE Aligned
  • UK Evidence-Based
  • Last Reviewed 22 July 2026

Professor Mohammed Mahdi Althaf

Consultant Nephrologist & Acute Physician

View Credentials

Professor Mohammed Mahdi Althaf

MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN

Consultant Nephrologist & Acute Physician · GMC 7216325

View profile →

Direct answer

Rare glomerular disease with PARALLEL MICROTUBULAR deposits 30–50 nm on EM. Often monoclonal, strongly linked to CLL/B-cell lymphoma and MGRS. Treat the clone — renal response follows haematological response.

Key recommendation: Hollow microtubules 30–50 nm in parallel arrays.

Quick answer

✓ Best choices

  • Plant proteins: beans, lentils, tofu, tempeh, chickpeas
  • Vegetables, fruit and whole grains
  • Oily fish 1–2 times a week
  • Olive oil as the main cooking fat

✓ Foods to limit

  • Added salt (≤ 6 g/day)
  • Processed meats and high-additive ready meals
  • Excess animal protein at every meal

Key takeaway

Rare glomerular disease with PARALLEL MICROTUBULAR deposits 30–50 nm on EM. Often monoclonal, strongly linked to CLL/B-cell lymphoma and MGRS. Treat the clone — renal response follows haematological response.

Who should be cautious

People on dialysis, post-transplant, pregnant or breastfeeding, or taking prescription medication — confirm with your renal team before changes.

Immunotactoid Glomerulopathy

Pathology

Light Microscopy

  • Mesangial expansion ± membranoproliferative pattern
  • Membranous-like thickening in some cases
  • Endocapillary or crescentic in aggressive disease

Immunofluorescence

  • IgG (often IgG1 or IgG3), C3 deposits
  • Light chain RESTRICTION (kappa or lambda) in most
  • Congo-red NEGATIVE

ELECTRON MICROSCOPY (diagnostic):

  • Parallel arrays of MICROTUBULAR deposits
  • Hollow core, diameter 30–50 nm (vs fibrillary 10–30 nm solid)
  • Subendothelial, mesangial, ± subepithelial location

Staining

  • DNAJB9 NEGATIVE (distinguishes from fibrillary GN)

Differential

  • Fibrillary GN (DNAJB9+, solid fibrils 10–30 nm)
  • Cryoglobulinaemic GN (curved microtubules + HCV)
  • Amyloid (Congo-red positive, smaller fibrils 8–12 nm)
  • Type I MPGN with organised deposits

Investigations & associations

Renal

  • 24-h urine protein or PCR (often nephrotic)
  • Microscopic haematuria common
  • eGFR usually mildly-moderately reduced at biopsy

HAEMATOLOGY WORK-UP (mandatory):

  • Serum + urine electrophoresis with immunofixation
  • Serum free light chains (κ/λ ratio)
  • Cryoglobulins (warm to lab)
  • HCV, HBV, HIV serology
  • Lymphocyte phenotyping (FBC, flow cytometry if lymphocytosis)
  • Bone marrow biopsy if monoclonal protein or abnormal FLC
  • CT chest/abdo/pelvis ± PET-CT for lymphoma staging

Associations

  • CLL / small lymphocytic lymphoma (commonest)
  • Other B-cell lymphomas
  • Multiple myeloma, MGUS / MGRS
  • Rarely autoimmune disease, idiopathic

Treatment & outcome

Principle

  • Treat the underlying B-cell clone (renal response follows haematological response)
  • Joint nephrology + haematology decision-making

Cll / B-cell Lymphoma

  • Chemo-immunotherapy: FCR, BR, or BTK inhibitor (ibrutinib, acalabrutinib)
  • Rituximab-containing regimens preferred
  • Venetoclax + obinutuzumab for fitter patients

Mgrs Without Overt Malignancy

  • Plasma cell clone: bortezomib + dexamethasone
  • B-cell clone: rituximab ± bendamustine
  • Clone-directed therapy guided by IMWG / UK MGRS Working Group

IDIOPATHIC / NO CLONE FOUND (rare):

  • ACE-i/ARB, supportive care
  • Rituximab in selected cases
  • Calcineurin inhibitors anecdotal

SUPPORTIVE (always):

  • ACE-i / ARB for proteinuria + hypertension
  • SGLT2 inhibitor (dapagliflozin, empagliflozin) for proteinuric CKD
  • Statins, anticoagulation if severely nephrotic
  • Vaccination (pre-rituximab if possible)

Prognosis

  • 5-year renal survival ~ 50–60% historical
  • Modern clone-directed therapy improves outcomes substantially
  • Disease can recur in renal allograft

UK Pathway

  • MGRS multidisciplinary clinic (nephrology + haematology)
  • National Amyloidosis Centre input for atypical cases
Fibrillary Glomerulonephritis
Related reading: Fibrillary Glomerulonephritis.

Key practical tips

Designed for quick scanning — what to order, what to avoid, sensible portions, common mistakes.

  • Take prescribed ACE inhibitor / ARB / SGLT2 inhibitor consistently — diet works alongside, not instead
  • Monitor BP at home weekly
  • Review urine ACR with your team to track progress

Clinical guidance

TL;DR summary

Rare glomerular disease with PARALLEL MICROTUBULAR deposits 30–50 nm on EM. Often monoclonal, strongly linked to CLL/B-cell lymphoma and MGRS. Treat the clone — renal response follows haematological response.

Key takeaways
  • Hollow microtubules 30–50 nm in parallel arrays.
  • DNAJB9 negative (cf. fibrillary GN positive).
  • Monoclonal Ig deposits in ≥ 70%.
  • Strong CLL / B-cell lymphoma association.
  • Treatment = haematology-led clone-directed therapy.
Kidney Diet & Nutrition Considerations

When protein is leaking into the urine, the goal is to protect the remaining kidney function. Dietary protein should be sensible — neither very high nor unnecessarily low — and a Mediterranean-style plate with reduced salt supports both blood pressure and albuminuria reduction alongside ACE inhibitors, ARBs or SGLT2 inhibitors.

Foods to prioritise

  • Plant proteins: beans, lentils, tofu, tempeh, chickpeas
  • Vegetables, fruit and whole grains
  • Oily fish 1–2 times a week
  • Olive oil as the main cooking fat

Foods to limit

  • Added salt (≤ 6 g/day)
  • Processed meats and high-additive ready meals
  • Excess animal protein at every meal

Potassium, phosphate and protein needs vary between individuals — please confirm personal targets with your renal team or dietitian. Browse the Kidney Diet Hub for more guides in this cluster.

Frequently asked questions

What is immunotactoid glomerulopathy?

Immunotactoid glomerulopathy (ITG) is a rare glomerular disease defined by organised, MICROTUBULAR (hollow-core) immunoglobulin deposits on electron microscopy (typically 30–50 nm diameter, arranged in parallel arrays). It accounts for < 0.06% of native kidney biopsies. Most cases are associated with a haematological disorder — chronic lymphocytic leukaemia (CLL), other B-cell lymphomas, or monoclonal gammopathy of renal significance (MGRS).

How does it differ from fibrillary GN?

Both show organised glomerular deposits but: FIBRILLARY GN — randomly arranged solid fibrils 10–30 nm, DNAJB9-positive, Congo-red-negative, usually polyclonal IgG. IMMUNOTACTOID — parallel arrays of hollow MICROTUBULES 30–50 nm, DNAJB9-negative, often MONOCLONAL Ig, strong association with CLL/B-cell lymphoma and MGRS. Distinction matters because immunotactoid mandates a haematology work-up.

How does it present?

Proteinuria (often nephrotic, > 3.5 g/day), microscopic haematuria, hypertension, CKD with declining eGFR over months. Some patients have constitutional symptoms of the underlying B-cell disorder. Bloods: monoclonal band on serum or urine electrophoresis or abnormal free light chain ratio in ≥ 50%, ± cryoglobulins, ± lymphocytosis (CLL).

What is the treatment?

Treat the underlying clone. CLL-associated: chemo-immunotherapy with rituximab-based regimens (e.g. FCR — fludarabine, cyclophosphamide, rituximab — or BR — bendamustine + rituximab — or BTK inhibitors like ibrutinib/acalabrutinib). MGRS without overt malignancy: clone-directed therapy guided by haematology (bortezomib for plasma cell clones, rituximab for B-cell clones). Renal response correlates with haematological response. ACE-i/ARB and supportive measures throughout.

Can diet reduce protein in urine?

A reduced-salt, Mediterranean-style diet with sensible protein intake can lower urine protein, particularly when combined with prescribed ACE inhibitors, ARBs or SGLT2 inhibitors. Very low-protein diets are not routinely recommended without dietitian supervision.

Nutritional challenges in kidney disease

Many people living with kidney disease have to limit foods because of potassium, phosphate, diabetes, dialysis, appetite changes or simply the time it takes to cook from scratch every day. That can make it harder to keep daily nutrition balanced — particularly for vitamins and minerals that food alone may not fully cover.

Kidney Vitality is a UK-formulated daily nutritional support product designed by Consultant Nephrologist Professor Mohammed Mahdi Althaf with renal nutrition in mind from the start. It keeps doses moderate, leaves out added potassium, phosphate and magnesium, and avoids megadose vitamin A — sitting alongside a kidney-friendly diet, not replacing it.

Why Kidney Vitality fits this need

Built around UK guidance

Aligned with KDIGO 2024 GN guideline, International Kidney and Monoclonal Gammopathy Research Group consensus and BSH lymphoma guidance.

Designed by a UK Consultant Nephrologist

Formulated and reviewed by Professor Mohammed Mahdi Althaf (GMC 7216325).

Haematology-led & MGRS-aware

Practical biopsy distinction from fibrillary GN and clone-directed treatment algorithm.

Designed by a UK Consultant Nephrologist

Ready to support your kidney health?

If you have been researching kidney health, supplements, CKD nutrition or kidney-friendly living, Kidney Vitality was developed specifically around those principles by Professor Mohammed Mahdi Althaf (GMC 7216325). Nephrologist Developed Daily Multivitamin.

  • No Added Potassium
  • No Added Magnesium
  • No Added Phosphorus
  • No Added Iron
  • One capsule daily
  • UK GMP — BRCGS, NSF GMP, Halal
Subscribe & Save — £20.39/monthCheck your current multivitamin

✓ Free UK tracked delivery  ·  ✓ Delivered every 30 days  ·  ✓ Pause or cancel anytime  ·  ✓ Never run out

ComparisonKidney VitalityTypical high-street multivitamin
Added potassiumNoneOften included
Added phosphateNoneOften included (E338–E452)
Vitamin A (retinol)No megadoseOften high-dose retinol
Kidney-focused formulationYesNo — general population
Consultant Nephrologist involvementYes (GMC 7216325)No
UK GMP manufacturedYes (BRCGS, NSF GMP)Varies

Food supplement. Not a medicine and not a treatment for kidney disease. Speak with your GP, pharmacist or renal team before starting any new supplement, especially in advanced CKD, on dialysis, post-transplant, pregnant or breastfeeding.

Clinical reviewer

Professor Mohammed Mahdi Althaf

Consultant Nephrologist

Acute Physician

GMC 7216325

View Full Biography

Professor Mohammed Mahdi Althaf is a UK Consultant Nephrologist and Acute Physician with a special interest in chronic kidney disease, AKI prevention and renal nutrition. He combines hospital practice with patient education and clinical guidance review.

View professional profile →
View Credentials
  • MD
  • MSc
  • PgDip (Clin Ed)
  • FRCP
  • FHEA
  • FASN

About this article

Written for UK patients and based on:

  • NICE guidance
  • NHS resources
  • British Dietetic Association guidance
  • Kidney Care UK resources
View methodology

Each article is researched against current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO and KDOQI international guidelines, and the British Dietetic Association Renal Nutrition Group. Drafts are written by the Kidney Vitality editorial team and reviewed by a UK Consultant Nephrologist before publication. Content is reviewed on a rolling basis and updated when guidance changes.

Editorial standards

  • Clinically reviewed
  • NHS-aligned
  • NICE-aligned
  • Evidence-based
  • Reviewed before publication
View full editorial process

Every article is researched and written by the Kidney Vitality editorial team using current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO/KDOQI international guidelines, and British Dietetic Association renal nutrition guidance. Drafts are reviewed for clinical accuracy by Professor Mohammed Mahdi Althaf, MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN (Consultant Nephrologist & Acute Physician, GMC 7216325) before publication. Content is updated when UK guidance changes.

References (4)View Sources
  1. NICE NG203: Chronic kidney disease — assessment and management
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
  3. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update
  4. British Dietetic Association — Renal Nutrition Group

Medical disclaimer

This content is educational only and does not replace personalised medical advice.

Read full disclaimer

This page is general information, not personal medical advice. If you have chronic kidney disease, are on dialysis, have had a kidney transplant, are pregnant or breastfeeding, or take prescription medication, please confirm any supplement with your GP, pharmacist or renal team before starting.

← Back to all guides